UNSPSC 51342313: Ganciclovir sodium

This classification denotes a purine antagonist and antiviral agent with the molecular formula C9H12N5O4.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 02L083W284, chemically known as 9-(1,3-dihydroxy-propoxymethane)guanine but more generally known as ganciclovir sodium, which bears US NIH Compound Identifier 3454. European Medicines Agency schedules Ganciclovir sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02312MIG.

Most nations, for tariff and trade purposes, schedule ganciclovir sodium under HS 29335995 and SITC 51576. As of Q4 2014, GANCICLOVIR SODIUM remains US FDA's Preferred Term for this commodity. Ganciclovir sodium bears US NLM identifiers UMLS ID C0282399 and NCI Concept Code C1588. SMILES: C1NC2C(=O)[N-]C(NC2N1COC(CO)CO)N.[NA+].

UNSPSC 51342313 Ganciclovir sodium is a Commodity code that nominally identifies a specific antiviral pharmaceutical ingredient, but recent state and local solicitations tagged under this code show little direct procurement activity for ganciclovir itself. Instead, the opportunities grouped under this code span a broader range of pharmaceutical, medical supply, and pharmacy benefit management work — including naloxone procurement, emergency medical supplies for fire departments, generic pharmaceuticals through cooperative purchasing, and direct-to-manufacturer prescription program design. The issuing bodies include county health departments (Seminole County, Florida), municipal fire services (Tampa), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing consortiums (Minnesota Multistate Cooperative Purchasing Alliance). This mismatch between the code's nominal scope and the actual work being solicited suggests the code may be used inconsistently in state and local systems or may serve as a catch-all for pharmaceutical-related procurements beyond ganciclovir specifically.

Recent opportunities concentrate in Florida and Texas, with broader multistate activity through the Minnesota-administered MMCAP cooperative. Representative current solicitations include Seminole County's IFB60459723LAS (due Jul 26, 2023) for naloxone and drug deactivation systems under an IFB notice; the City of Tampa's 26P00145 (due Mar 13, 2026) for medical and first aid supplies for the Fire Department Rescue Division under an IFB, estimated at $700,000 and designated as a small local business enterprise sheltered market with a 5 percent bid discount; the Texas HHS Commission's RFI HHS0017013 (due Apr 3, 2026) seeking vendor capabilities for direct-to-manufacturer prescription programs; and the Minnesota Department of Administration's MMCAP RFP S1070000015802 (due Mar 26, 2026) for generic multi-source pharmaceuticals and over-the-counter products through authorized wholesalers across multiple states. The code shows active procurement momentum in cooperative purchasing vehicles and emergency medical supply chains, though ganciclovir-specific procurement is not evident in the recent record.